|
US4657760A
(en)
|
1979-03-20 |
1987-04-14 |
Ortho Pharmaceutical Corporation |
Methods and compositions using monoclonal antibody to human T cells
|
|
US4469863A
(en)
|
1980-11-12 |
1984-09-04 |
Ts O Paul O P |
Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US5206344A
(en)
|
1985-06-26 |
1993-04-27 |
Cetus Oncology Corporation |
Interleukin-2 muteins and polymer conjugation thereof
|
|
US4676980A
(en)
|
1985-09-23 |
1987-06-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Target specific cross-linked heteroantibodies
|
|
GB8601597D0
(en)
|
1986-01-23 |
1986-02-26 |
Wilson R H |
Nucleotide sequences
|
|
US6548640B1
(en)
|
1986-03-27 |
2003-04-15 |
Btg International Limited |
Altered antibodies
|
|
US5567610A
(en)
|
1986-09-04 |
1996-10-22 |
Bioinvent International Ab |
Method of producing human monoclonal antibodies and kit therefor
|
|
DE3850542T2
(de)
|
1987-09-23 |
1994-11-24 |
Bristol Myers Squibb Co |
Antikörper-Heterokonjugate zur Töting von HIV-infizierten Zellen.
|
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
|
US5175384A
(en)
|
1988-12-05 |
1992-12-29 |
Genpharm International |
Transgenic mice depleted in mature t-cells and methods for making transgenic mice
|
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
|
ATE144793T1
(de)
|
1989-06-29 |
1996-11-15 |
Medarex Inc |
Bispezifische reagenzien für die aids-therapie
|
|
US5225212A
(en)
|
1989-10-20 |
1993-07-06 |
Liposome Technology, Inc. |
Microreservoir liposome composition and method
|
|
US5959177A
(en)
|
1989-10-27 |
1999-09-28 |
The Scripps Research Institute |
Transgenic plants expressing assembled secretory antibodies
|
|
DE69133566T2
(de)
|
1990-01-12 |
2007-12-06 |
Amgen Fremont Inc. |
Bildung von xenogenen Antikörpern
|
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US5321131A
(en)
|
1990-03-08 |
1994-06-14 |
Hybridon, Inc. |
Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling
|
|
US5229275A
(en)
|
1990-04-26 |
1993-07-20 |
Akzo N.V. |
In-vitro method for producing antigen-specific human monoclonal antibodies
|
|
JPH06500011A
(ja)
|
1990-06-29 |
1994-01-06 |
ラージ スケール バイオロジー コーポレイション |
形質転換された微生物によるメラニンの製造
|
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
KR100272077B1
(ko)
|
1990-08-29 |
2000-11-15 |
젠팜인터내셔날,인코포레이티드 |
이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
|
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
|
US5625126A
(en)
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
US5571894A
(en)
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
|
WO1992020373A1
(en)
|
1991-05-14 |
1992-11-26 |
Repligen Corporation |
Heteroconjugate antibodies for treatment of hiv infection
|
|
DK51092D0
(da)
|
1991-05-24 |
1992-04-15 |
Ole Buchardt |
Oligonucleotid-analoge betegnet pna, monomere synthoner og fremgangsmaade til fremstilling deraf samt anvendelser deraf
|
|
US5719262A
(en)
|
1993-11-22 |
1998-02-17 |
Buchardt, Deceased; Ole |
Peptide nucleic acids having amino acid side chains
|
|
WO1993006217A1
(en)
|
1991-09-19 |
1993-04-01 |
Genentech, Inc. |
EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
|
|
US5565332A
(en)
|
1991-09-23 |
1996-10-15 |
Medical Research Council |
Production of chimeric antibodies - a combinatorial approach
|
|
FI941572L
(fi)
|
1991-10-07 |
1994-05-27 |
Oncologix Inc |
Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
|
|
WO1993008829A1
(en)
|
1991-11-04 |
1993-05-13 |
The Regents Of The University Of California |
Compositions that mediate killing of hiv-infected cells
|
|
AU3178993A
(en)
|
1991-11-25 |
1993-06-28 |
Enzon, Inc. |
Multivalent antigen-binding proteins
|
|
US5700922A
(en)
|
1991-12-24 |
1997-12-23 |
Isis Pharmaceuticals, Inc. |
PNA-DNA-PNA chimeric macromolecules
|
|
ATE419355T1
(de)
|
1992-02-06 |
2009-01-15 |
Novartis Vaccines & Diagnostic |
Marker für krebs und biosynthetisches bindeprotein dafür
|
|
US5573905A
(en)
|
1992-03-30 |
1996-11-12 |
The Scripps Research Institute |
Encoded combinatorial chemical libraries
|
|
WO1994002499A1
(en)
|
1992-07-27 |
1994-02-03 |
Hybridon, Inc. |
Oligonucleotide alkylphosphonothioates
|
|
ATE149570T1
(de)
|
1992-08-17 |
1997-03-15 |
Genentech Inc |
Bispezifische immunoadhesine
|
|
CA2154358A1
(en)
|
1993-01-21 |
1994-08-04 |
Hybridon, Inc. |
Integrated oligonucleotides
|
|
US5637684A
(en)
|
1994-02-23 |
1997-06-10 |
Isis Pharmaceuticals, Inc. |
Phosphoramidate and phosphorothioamidate oligomeric compounds
|
|
US5789199A
(en)
|
1994-11-03 |
1998-08-04 |
Genentech, Inc. |
Process for bacterial production of polypeptides
|
|
US5840523A
(en)
|
1995-03-01 |
1998-11-24 |
Genetech, Inc. |
Methods and compositions for secretion of heterologous polypeptides
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US5641870A
(en)
|
1995-04-20 |
1997-06-24 |
Genentech, Inc. |
Low pH hydrophobic interaction chromatography for antibody purification
|
|
US5739277A
(en)
|
1995-04-14 |
1998-04-14 |
Genentech Inc. |
Altered polypeptides with increased half-life
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
JP4312259B2
(ja)
|
1995-04-27 |
2009-08-12 |
アムジェン フレモント インク． |
免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体
|
|
EP0823941A4
(en)
|
1995-04-28 |
2001-09-19 |
Abgenix Inc |
HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
|
|
US5962674A
(en)
|
1995-06-01 |
1999-10-05 |
Hybridon, Inc. |
Synthesis of oligonucleotides containing alkylphosphonate internucleoside linkages
|
|
US6140482A
(en)
|
1995-06-01 |
2000-10-31 |
Hybridon, Inc. |
Primary phosphoramidate internucleoside linkages and oligonucleotides containing the same
|
|
US5955599A
(en)
|
1995-06-01 |
1999-09-21 |
Hybridon, Inc. |
Process for making oligonucleotides containing o- and s- methylphosphotriester internucleoside linkages
|
|
US5614622A
(en)
|
1995-06-01 |
1997-03-25 |
Hybridon, Inc. |
5-pentenoyl moiety as a nucleoside-amino protecting group, 4-pentenoyl-protected nucleotide synthons, and related oligonucleotide syntheses
|
|
US5637683A
(en)
|
1995-07-13 |
1997-06-10 |
Cornell Research Foundation, Inc. |
Nucleic acid analog with amide linkage and method of making that analog
|
|
US5652356A
(en)
|
1995-08-17 |
1997-07-29 |
Hybridon, Inc. |
Inverted chimeric and hybrid oligonucleotides
|
|
AU7378096A
(en)
|
1995-09-28 |
1997-04-17 |
Alexion Pharmaceuticals, Inc. |
Porcine cell interaction proteins
|
|
DE19544393A1
(de)
|
1995-11-15 |
1997-05-22 |
Hoechst Schering Agrevo Gmbh |
Synergistische herbizide Mischungen
|
|
US6117992A
(en)
|
1996-08-26 |
2000-09-12 |
Hybridon, Inc. |
Reagents and process for synthesis of oligonucleotides containing phosphorodithioate internucleoside linkages
|
|
US5886165A
(en)
|
1996-09-24 |
1999-03-23 |
Hybridon, Inc. |
Mixed backbone antisense oligonucleotides containing 2'-5'-ribonucleotide- and 3'-5'-deoxyribonucleotides segments
|
|
DE69738539T2
(de)
|
1996-12-03 |
2009-03-26 |
Amgen Fremont Inc. |
Vollkommen humane Antikörper die EGFR binden
|
|
US5739314A
(en)
|
1997-04-25 |
1998-04-14 |
Hybridon, Inc. |
Method for synthesizing 2'-O-substituted pyrimidine nucleosides
|
|
US6040498A
(en)
|
1998-08-11 |
2000-03-21 |
North Caroline State University |
Genetically engineered duckweed
|
|
JP4460155B2
(ja)
|
1997-12-05 |
2010-05-12 |
ザ・スクリプス・リサーチ・インステイチユート |
マウス抗体のヒト化
|
|
US6506559B1
(en)
|
1997-12-23 |
2003-01-14 |
Carnegie Institute Of Washington |
Genetic inhibition by double-stranded RNA
|
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
|
DE19956568A1
(de)
|
1999-01-30 |
2000-08-17 |
Roland Kreutzer |
Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
|
|
WO2000056746A2
(en)
|
1999-03-24 |
2000-09-28 |
Exiqon A/S |
Improved synthesis of [2.2.1]bicyclo nucleosides
|
|
KR20010001577A
(ko)
|
1999-06-07 |
2001-01-05 |
윤종용 |
고분자 광산발생제를 이용한 올리고펩티드 핵산 탐침의 제조방법
|
|
AU6629200A
(en)
|
1999-08-25 |
2001-03-19 |
Philip P Garner |
Alpha-helical peptide nucleic acid alpha-pna
|
|
JP2003512821A
(ja)
|
1999-10-04 |
2003-04-08 |
メディカゴ インコーポレイテッド |
外来性遺伝子の転写調節方法
|
|
US7125978B1
(en)
|
1999-10-04 |
2006-10-24 |
Medicago Inc. |
Promoter for regulating expression of foreign genes
|
|
HK1047109A1
(zh)
|
1999-10-15 |
2003-02-07 |
University Of Massachusetts |
作为指定基因干预工具的rna干预轨迹基因
|
|
GB9927444D0
(en)
|
1999-11-19 |
2000-01-19 |
Cancer Res Campaign Tech |
Inhibiting gene expression
|
|
JP2001352977A
(ja)
*
|
2000-06-12 |
2001-12-25 |
Kirin Brewery Co Ltd |
樹状細胞（ＤＣ）膜分子Ｓｉｇｌｅｃ−９に対する抗体、並びにそれを用いたＤＣ検出法及びＤＣ分離法
|
|
AU2002319207B2
(en)
*
|
2001-06-19 |
2007-03-01 |
Reinhard Brossmer |
Sialic acid derivatives for use as siglec inhibitors
|
|
US6455308B1
(en)
|
2001-08-01 |
2002-09-24 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of serum amyloid A4 expression
|
|
JP2006504971A
(ja)
|
2002-11-01 |
2006-02-09 |
ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・コロラド，ア・ボディー・コーポレイト |
マトリックス支援レーザー脱離イオン化−飛行時間型質量分析によるタンパク質アイソフォームの定量的解析
|
|
KR20070107687A
(ko)
|
2004-12-31 |
2007-11-07 |
제넨테크, 인크. |
Ｂｒ３과 결합하는 폴리펩티드, 및 그의 용도
|
|
US7700099B2
(en)
|
2005-02-14 |
2010-04-20 |
Merck & Co., Inc. |
Non-immunostimulatory antibody and compositions containing the same
|
|
GB0521991D0
(en)
|
2005-10-28 |
2005-12-07 |
Univ Dundee |
Siglec-9 binding agents
|
|
DK2359834T5
(en)
|
2006-03-15 |
2017-02-06 |
Alexion Pharma Inc |
Treatment of paroxysmal nocturnal hemoglobinuria patients with a complement inhibitor
|
|
UY30776A1
(es)
|
2006-12-21 |
2008-07-03 |
Medarex Inc |
Anticuerpos cd44
|
|
JP5142265B2
(ja)
*
|
2007-05-28 |
2013-02-13 |
独立行政法人産業技術総合研究所 |
抗モータリン抗体のパラトープ及びエピトープ
|
|
CA2697193C
(en)
|
2007-09-14 |
2017-06-06 |
Adimab, Inc. |
Rationally designed, synthetic antibody libraries and uses therefor
|
|
US8877688B2
(en)
|
2007-09-14 |
2014-11-04 |
Adimab, Llc |
Rationally designed, synthetic antibody libraries and uses therefor
|
|
FR2945538B1
(fr)
|
2009-05-12 |
2014-12-26 |
Sanofi Aventis |
Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
|
|
WO2012009568A2
(en)
|
2010-07-16 |
2012-01-19 |
Adimab, Llc |
Antibody libraries
|
|
US9322581B2
(en)
|
2011-02-11 |
2016-04-26 |
Johnson Controls Technology Company |
HVAC unit with hot gas reheat
|
|
CA2862222A1
(en)
*
|
2012-01-20 |
2013-07-25 |
Genzyme Corporation |
Anti-cxcr3 antibodies
|
|
EP2937088B1
(en)
|
2012-12-21 |
2020-11-18 |
Tokushima University |
Composition having tissue repairing activity and utilization thereof
|
|
WO2016038064A1
(en)
*
|
2014-09-10 |
2016-03-17 |
Innate Pharma |
Cross reactive siglec antibodies
|
|
JP7060502B2
(ja)
*
|
2015-10-29 |
2022-04-26 |
アレクトル エルエルシー |
抗Ｓｉｇｌｅｃ－９抗体及びその使用方法
|
|
EP3402516A4
(en)
|
2016-01-12 |
2020-01-08 |
Palleon Pharmaceuticals Inc. |
USE OF ANTIBODIES DIRECTED AGAINST SIGLEC-7 OR SIGLEC-9 IN THE TREATMENT OF CANCER
|
|
CN108699158B
(zh)
|
2016-03-08 |
2022-06-03 |
依奈特制药公司 |
Siglec中和抗体
|
|
US20190300606A1
(en)
|
2016-07-01 |
2019-10-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Inhibitory Immune Receptor Inhibition Methods and Compositions
|
|
GB201611535D0
(en)
|
2016-07-01 |
2016-08-17 |
King S College London |
Methods and compositions for treating cancer with siglec-9 activity modulators
|